Adaptive immune responses to SARS-CoV-2.
TLDR
In this paper, a review of adaptive immune responses against SARS-CoV-2, the coronavirus that causes COVID-19, is presented, focusing on the role of antibody and T-cell responses.About:
This article is published in Advanced Drug Delivery Reviews.The article was published on 2021-05-01 and is currently open access. It has received 6 citations till now. The article focuses on the topics: Immune system.read more
Citations
More filters
Journal ArticleDOI
SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
Polina Sonis,Mark Dolev,Shay Menascu,Jorge Daniel Czajkowski,R. T. Pardasani,Ohiniko M. Toffa,Zuobing Xiao,Ina Nietzschmann,Richard Schwens +8 more
TL;DR: In this article , a cross-sectional and longitudinal study, blood-derived MBC and MTC responses were evaluated in 68 anti-spike IgG-positive mild coronavirus disease 2019 (COVID-19) convalescents at visit 1, between 1 and 7 months (median 4.1 months) after disease onset.
Journal ArticleDOI
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
TL;DR: How cellular immunity is the axis around which the rest of the immune system components revolve is discussed, since it orchestrates and leads antiviral response by regulating the inflammatory cascade and, as a consequence, the innate immune system, as well as promoting a correct humoral response through CD4+ Tfh cells.
Journal ArticleDOI
BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus
Jorge A. Soto,Fabián E. Díaz,Angello Retamal-Díaz,Nicolás M. S. Gálvez,Felipe Melo-Gonzalez,Alejandro Piña-Iturbe,Mario A. Ramirez,Karen Bohmwald,Pablo A. González,Susan M. Bueno,Alexis M. Kalergis +10 more
TL;DR: The BCG vaccine is a promising platform for developing vaccines against different pathogens, inducing a marked antigen-specific immune response, and related to a trained immunity profile.
Journal ArticleDOI
When RING finger family proteins meet SARS‐CoV‐2
TL;DR: Understanding the crosstalk between RNF proteins and SARS‐CoV‐2 infection would help design potential novel targets for COVID‐19 treatment and discuss the diverse antiviral mechanisms of R NF proteins and viral immune evasion in an RNF protein‐dependent manner.
Journal ArticleDOI
Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
TL;DR: A dendritic cell-based vaccine for SARS-CoV-2 has the potential to be an effective vaccine that solves existing problems and is summarized by summarizing the crucial role of dendedritic cells in the formation of T cell immunity.
References
More filters
Journal ArticleDOI
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Sheng-Fan Wang,Sheng-Fan Wang,Sung-Pin Tseng,Chia-Hung Yen,Jyh Yuan Yang,Ching Han Tsao,Chun Wei Shen,Kuan Hsuan Chen,Fu-Tong Liu,Wu Tse Liu,Yi Ming Arthur Chen,Jason C. Huang +11 more
TL;DR: Quantitative-PCR and immunofluorescence staining results indicate that SARS-CoV is capable of replication in HL-CZ cells, and of displaying virus-induced cytopathic effects and increased levels of TNF-α, IL-4 and IL-6 two days post-infection, while data from infectivity assays indicate that antibodies against SARsCoV spike proteins may trigger ADE effects.
Posted ContentDOI
Evolution of Antibody Immunity to SARS-CoV-2
Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor A. Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Jim Yee,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Thomas Hagglof,Robert E. Schwartz,Yaron Bram,Gustavo Martinez-Delgado,Pilar Mendoza,Gaëlle Breton,Juan Dizon,Cecille Unson-O'Brien,Roshni Patel +41 more
TL;DR: The memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response.
Posted ContentDOI
Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience
Michael J. Joyner,Jonathon W. Senefeld,Stephen A. Klassen,John Mills,Patrick W. Johnson,Elitza S. Theel,Chad C. Wiggins,Katelyn A. Bruno,Allan M. Klompas,Elizabeth R. Lesser,Katie L. Kunze,Matthew A. Sexton,Juan C. Diaz Soto,Sarah E. Baker,John R. A. Shepherd,Noud van Helmond,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Robert F. Rea,David O. Hodge,Vitaly Herasevich,Emily R. Whelan,Andrew J. Clayburn,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew R. Buras,Matthew N.P. Vogt,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Nigel Paneth,DeLisa Fairweather,R. Scott Wright,Rickey E. Carter,Arturo Casadevall +37 more
TL;DR: The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels provide signatures of efficacy for convalescent plasma in the treatment of hospitalized COVID-19 patients.
Journal ArticleDOI
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
Tyler J. Ripperger,Jennifer L. Uhrlaub,Makiko Watanabe,Rachel O.L. Wong,Rachel O.L. Wong,Yvonne Castaneda,Hannah A. Pizzato,Hannah A. Pizzato,Mallory R. Thompson,Christine M. Bradshaw,Craig Weinkauf,Christian Bime,Heidi Erickson,Kenneth S. Knox,Billie Bixby,Sairam Parthasarathy,Sachin Chaudhary,Bhupinder Natt,Elaine Cristan,Tammer El Aini,Franz Rischard,Janet Campion,Madhav Chopra,Michael Insel,Afshin Sam,James Knepler,Andrew P. Capaldi,Catherine M. Spier,Michael D. Dake,Taylor Edwards,Matthew E. Kaplan,Serena Jain Scott,Cameron Hypes,Jarrod Mosier,David T. Harris,Bonnie LaFleur,Ryan Sprissler,Janko Nikolich-Žugich,Deepta Bhattacharya +38 more
TL;DR: It is concluded that neutralizing antibodies are stably produced for at least 5-7 months after SARS-CoV-2 infection.
Journal ArticleDOI
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Jakob Kreye,S. Momsen Reincke,Hans Christian Kornau,Hans Christian Kornau,Elisa Sanchez-Sendin,Elisa Sanchez-Sendin,Elisa Sanchez-Sendin,Victor M. Corman,Hejun Liu,Meng Yuan,Nicholas C. Wu,Xueyong Zhu,Chang-Chun D Lee,Jakob Trimpert,Markus Höltje,Kristina Dietert,Laura Stöffler,Laura Stöffler,Niels von Wardenburg,Niels von Wardenburg,Scott van Hoof,Scott van Hoof,Scott van Hoof,Marie A Homeyer,Marie A Homeyer,Julius Hoffmann,Julius Hoffmann,Azza Abdelgawad,Achim D. Gruber,Luca D. Bertzbach,Daria Vladimirova,Lucie Y Li,Lucie Y Li,Paula Charlotte Barthel,Karl Skriner,Andreas C. Hocke,Stefan Hippenstiel,Martin Witzenrath,Norbert Suttorp,Florian Kurth,Florian Kurth,Christiana Franke,Matthias Endres,Dietmar Schmitz,Dietmar Schmitz,Lara Maria Jeworowski,Anja Richter,Marie Luisa Schmidt,Tatjana Schwarz,Marcel A. Müller,Christian Drosten,Daniel Wendisch,Leif E. Sander,Nikolaus Osterrieder,Nikolaus Osterrieder,Ian A. Wilson,Harald Prüss,Harald Prüss,Harald Prüss +58 more
TL;DR: Results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy and should be guided by immunization strategies.